Neue Suche | Kongressdetail
mail
Druckansicht
 
 

7th Neuropsychiatric Drug Development Summit

Evvnt Promotion / evvnt
-
24.09.2024 - 26.09.2024  Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
 
Kongressthemen
With Karuna's schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.
Kongressorganizer (PCO)
Hanson Wade Group
Anmerkungen
URL:
Brochure: https://go.evvnt.com/2433814-3?pid=4832

Speakers: Aaron Koenig, Chief Medical Officer, Delix Therapeutics, Ariana Mullin, Director, Regulatory Affairs, Bristol Myers Squibb, and more
 

Anfragen und Anmeldung:

https://go.evvnt.com/2433814-2?pid=4832
Frau Erin Thomas
 
Kategorien
Allgemeinmedizin
Sprache
Englisch
Kongressgebühr
Drug Developer Pricing - Conference + Workshop Day: USD 3597.00, Drug Developer Pricing - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + Workshop Day: USD 5197.00, Solution Provider Pricing - Conference Only: USD 3699.00
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

Helix - Forschung & Beratung WienOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Center of ExcellencenewTreeAMREF - African Medical and Research FoundationAnästhesie in Entwicklungsländern e. V.AGEM - Arbeitsgemeinschaft Ethnologie und MedizinCharité International Academy